Natco Pharma, one of the few outperformers in the pharma pack until recently, has seen its share price fall by a fourth since its January high of Rs 1,050. While the launch of copaxone generics (oncology treatment) in the US was among the key reasons for earlier gains, some disappointment in the December quarter (Q3) results, coupled with weakness in broader markets, contributed to the recent correction.
Nevertheless, this fall offers investors an opportunity, given the company’s strong future prospects, say analysts. In Q3, Natco’s revenues fell 16 per cent ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Fri, February 23 2018. 19:13 IST
RECOMMENDED FOR YOU